87743-10-0

Upstream product

• 50-00-0 formaldehyd 
• 121-33-5 vanillin 
• 124-40-3 dimethyl amine 

Downstream Products

• 2931-90-0 5-formylvanillin 
• 2134-91-0 4-hydroxy-5-methoxyisophthalic acid 
• 28276-04-2 3-(chloromethyl)-4-hydroxy-5-methoxybenzaldehyde 
• 1198079-04-7 C₂₄H₂₈N₂O₆S₂ 
• 1198079-02-5 C₁₄H₁₅NO₄S₂ 
• 46274-23-1 2-(3,4-dimethoxy-5-methylphenyl)ethan-1-amine 
• 3153-96-6 1,2-dimethoxy-3-methyl-5-(2-nitro-vinyl)benzene 
• 80547-80-4 3,4-dimethoxy-5-methylbenzaldehyde 
• 82628-68-0 3,4-dihydroxy-5-methylbenzaldehyde 
• 32263-14-2 4-hydroxy-3-methoxy-5-methylbenzaldehyde 
• 87743-11-1 Acetic acid 2-acetoxymethyl-4-formyl-6-methoxy-phenyl ester 

Relevant academic research and scientific papers

Application of conjugate of polyethylene glycol and local anesthetic to non-narcotic analgesia

The invention discloses application of a conjugate of polyethylene glycol and local anesthetic to non-narcotic analgesia. The local anesthetic is made into a prodrug or a sustained release preparation, wherein high-molecular polymers such as polyethylene glycol in the prodrug are covalently bonded with local anesthetic, and auxiliary materials with a sustained release function in the sustained release preparation are covalently bonded with the local anesthetic. After application of the conjugate, anesthesia and analgesia effects are not achieved until release of free local anesthetic, and an analgesia effect is achieved after release of the free local anesthetic. Due to low release speed of the prodrug or the sustained release preparation of the local anesthetic, drug concentration can bestably and enduringly kept in an effective concentration range of non-narcotic analgesia, long-acting non-narcotic analgesia effects can be achieved while remarkable reduction of clinical untoward effects of the local anesthetic and reduction of dosing frequency are realized, drug effectiveness is improved, and a clinical application range of the local anesthetic is expanded.

2-THIOXOTHIAZOLIDIN-4-ONE DERIVATIVES ACTIVE AS TRANSTHYRETIN LIGANDS AND USES THEREOF

Compounds of formula (II) are provided for stabilizing protein transthyretin (TTR) and inhibiting amyloid fibril formation, for example, transthyretin-mediated amyloid fibril formation, and for treating, preventing, or ameliorating one or more symptoms of amyloid diseases, for example, transthyretin-related amyloidosis (ATTR).

Tetrahydrocoptisine derivative and applications thereof

The present invention relates to a compound as shown in a formula (VII), a preparation method and applications thereof in medicines. In particular, the present invention relates to a derivative of the compound as shown in the formula (VII), a preparation method, and the applications of the derivative used as a therapeutic agent in prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, II-type diabetes, hyperglycemia, obesity or insulin resistance syndrome and metabolic syndrome. The compound disclosed by the present invention can also reduce total cholesterol, LDL-cholesterol and triglyceride, and increases expression of a liver LDL receptor and decreases expression of PCSK9.

AGENT FOR DYEING KERATIN-CONTAINING FIBERS

The invention relates to an agent for dying fibers comprising keratin, particularly human hair, the agent comprising at least one compound of the formula: together with at least one CH-acidic compound. The invention also relates to methods for shading oxidation dyed fibers, methods for freshening up fibers, methods for making an agent for dyeing fibers and to various compositions.

An expeditious and convergent synthesis of ailanthoidol

An expeditious and concise method has been described for the synthesis of ailanthoidol through convergent route starting from vanillin. The protocol involving intramolecular Wittig as a key reaction afforded ailanthoidol in overall high yield.